Literature DB >> 19404150

Perioperative fever and outcome in surgical patients with aneurysmal subarachnoid hemorrhage.

Michael M Todd1, Bradley J Hindman, William R Clarke, James C Torner, Julie B Weeks, Emine O Bayman, Qian Shi, Christina M Spofford.   

Abstract

OBJECTIVE: We examined the incidence of perioperative fever and its relationship to outcome among patients enrolled in the Intraoperative Hypothermia for Aneurysm Surgery Trial.
METHODS: One thousand patients with initial World Federation of Neurological Surgeons grades of I to III undergoing clipping of intracranial aneurysms after subarachnoid hemorrhage were randomized to intraoperative normothermia (36 degrees C-37 degrees C) or hypothermia (32.5 degrees C-33.5 degrees C). Fever (> or =38.5 degrees C) and other complications (including infections) occurring between admission and discharge (or death) were recorded. Functional and neuropsychologic outcomes were assessed 3 months postoperatively. The primary outcome variable for the trial was dichotomized Glasgow Outcome Scale (good outcome versus all others).
RESULTS: Fever was reported in 41% of patients. In 97% of these, fever occurred in the postoperative period. The median time from surgery to first fever was 3 days. All measures of outcome were worse in patients who developed fever, even in those without infections or who were World Federation of Neurological Surgeons grade I. Logistic regression analyses were performed to adjust for differences in preoperative factors (e.g., age, Fisher grade, initial neurological status). This demonstrated that fever continued to be significantly associated with most outcome measures, even when infection was added to the model. An alternative stepwise model selection process including all fever-related measures from the preoperative and intraoperative period (e.g., hydrocephalus, duration of surgery, intraoperative blood loss) resulted in the loss of significance for dichotomized Glasgow Outcome Scale, but significant associations between fever and several other outcome measures remained. After adding postoperative delayed ischemic neurological deficits to the model, only worsened National Institutes of Health Stroke Scale score, Barthel Activities of Daily Living index, and discharge destination (home versus other) remained independently associated with fever.
CONCLUSION: These findings suggest that fever is associated with worsened outcome in surgical subarachnoid hemorrhage patients, although, because the association between fever and the primary outcome measure for the trial is dependent on the covariates used in the analysis (particularly operative events and delayed ischemic neurological deficits), we cannot rule out the possibility that fever is a marker for other events. Only a formal trial of fever treatment or prevention can address this issue.

Entities:  

Mesh:

Year:  2009        PMID: 19404150     DOI: 10.1227/01.NEU.0000341903.11527.2F

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  19 in total

Review 1.  Intracranial hemorrhage.

Authors:  Andrew M Naidech
Journal:  Am J Respir Crit Care Med       Date:  2011-11-01       Impact factor: 21.405

Review 2.  Fever management in SAH.

Authors:  V Scaravilli; G Tinchero; G Citerio
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

3.  Refining the Association of Fever with Functional Outcome in Aneurysmal Subarachnoid Hemorrhage.

Authors:  Christopher L Kramer; Marianna Pegoli; Jay Mandrekar; Giuseppe Lanzino; Alejandro A Rabinstein
Journal:  Neurocrit Care       Date:  2017-02       Impact factor: 3.210

4.  Perioperative hypothermia (33 degrees C) does not increase the occurrence of cardiovascular events in patients undergoing cerebral aneurysm surgery: findings from the Intraoperative Hypothermia for Aneurysm Surgery Trial.

Authors:  Hoang P Nguyen; Jonathan G Zaroff; Emine O Bayman; Adrian W Gelb; Michael M Todd; Bradley J Hindman
Journal:  Anesthesiology       Date:  2010-08       Impact factor: 7.892

5.  Time from onset of SIRS to antibiotic administration and outcomes after subarachnoid hemorrhage.

Authors:  Elan L Guterman; Hooman Kamel; Carmil Azran; Maulik P Shah; J Claude Hemphill; Wade S Smith; Babak B Navi
Journal:  Neurocrit Care       Date:  2014-08       Impact factor: 3.210

6.  Predictors of Functional Outcome After Subdural Hematoma: A Prospective Study.

Authors:  Jonathan M Weimer; Errol Gordon; Jennifer A Frontera
Journal:  Neurocrit Care       Date:  2017-02       Impact factor: 3.210

Review 7.  Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference.

Authors:  Michael N Diringer; Thomas P Bleck; J Claude Hemphill; David Menon; Lori Shutter; Paul Vespa; Nicolas Bruder; E Sander Connolly; Giuseppe Citerio; Daryl Gress; Daniel Hänggi; Brian L Hoh; Giuseppe Lanzino; Peter Le Roux; Alejandro Rabinstein; Erich Schmutzhard; Nino Stocchetti; Jose I Suarez; Miriam Treggiari; Ming-Yuan Tseng; Mervyn D I Vergouwen; Stefan Wolf; Gregory Zipfel
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

Review 8.  Therapeutic hypothermia and targeted temperature management in traumatic brain injury: Clinical challenges for successful translation.

Authors:  W Dalton Dietrich; Helen M Bramlett
Journal:  Brain Res       Date:  2015-12-30       Impact factor: 3.252

9.  Safety of intraoperative hypothermia for patients: meta-analyses of randomized controlled trials and observational studies.

Authors:  He Xu; Zijing Wang; Xin Guan; Yijuan Lu; Daniel Charles Malone; Jack Warren Salmon; Aixia Ma; Wenxi Tang
Journal:  BMC Anesthesiol       Date:  2020-08-15       Impact factor: 2.217

10.  Influence of Fever and hospital-acquired infection on the incidence of delayed neurological deficit and poor outcome after aneurysmal subarachnoid hemorrhage.

Authors:  G Logan Douds; Bi Tadzong; Akash D Agarwal; Satish Krishnamurthy; Erik B Lehman; Kevin M Cockroft
Journal:  Neurol Res Int       Date:  2012-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.